Indication

Respiratory distress syndrome in the newborn

Respiratory distress syndrome in the newborn, historically termed hyaline membrane disease, is an acute pulmonary disorder that predominantly affects premature infants due to developmental insufficiency of pulmonary surfactant production and structural lung immaturity. Read more about Respiratory distress syndrome in the newborn

5 drugs 5 manufacturers

Advertisement

Drugs that treat it

Common Respiratory distress syndrome in the newborn therapies.

Showing 1–5 of 5 drugs

Filter & compare in the drug finder →Opens the drug finder with Respiratory distress syndrome in the newborn preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Respiratory distress syndrome in the newborn.

Respiratory distress syndrome in the newborn, historically termed hyaline membrane disease, is an acute pulmonary disorder that predominantly affects premature infants due to developmental insufficiency of pulmonary surfactant production and structural lung immaturity.

Deficient surfactant leads to increased alveolar surface tension, resulting in widespread microatelectasis, decreased lung compliance, ventilation-perfusion mismatch, and progressive hypoxemia.

Clinically, affected neonates present shortly after birth with marked signs of respiratory compromise, including tachypnea, intercostal and subcostal retractions, expiratory grunting, nasal flaring, and cyanosis.

Without prompt intervention, the condition can advance to respiratory failure and severe acidosis.

Personalize your experience

Follow Respiratory distress syndrome in the newborn and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it